注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Avidity Biosciences Inc是一家生物製藥公司。該公司致力於提供一種稱為抗體寡核苷酸結合物(AOC)的核糖核酸(RNA)療法。該公司利用其AOC平台設計、設計和開發治療學,將單克隆抗體(MAB)的特異性與寡核苷酸療法的精確性結合起來,以針對以前無法用這種療法治療的疾病的根本原因。其主要候選產品AOC 1001旨在治療強直性肌營養不良1型(DM1),這是一種罕見的單基因肌肉疾病。該公司推進和擴大的管道還包括AOC 1044,它是治療杜氏肌營養不良症(DMD)的三個項目的領導者,以及AOC 1020,它旨在治療面肩肱型肌營養不良症(FSHD)。AOC 1020由其單克隆抗體組成,其設計用於結合TfR1,並與靶向DUX4 mRNA的siRNA結合,作為靜脈輸注。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Christopher J. Kirk | 50 | - | Member of Scientific Advisory Board |
Anna M. Wu | - | - | Member of Scientific Advisory Board |
Jean Jinsun Kim | 48 | 2021 | Independent Director |
Richard A. Heyman | 65 | - | Member of Scientific Advisory Board |
Sarah Boyce | 50 | 2019 | President, CEO & Director |
Eran Nadav | 53 | - | Observer |
Ryan B. Corcoran | - | - | Member of Scientific Advisory Board |
Tamar Thompson | 48 | 2021 | Independent Director |
Frank P. McCormick | 74 | 2012 | Scientific Founder & Member of Scientific Advisory Board |
Troy Edward Wilson | 55 | 2012 | Co-Founder & Independent Chairman |
Arthur A. Levin | 70 | 2019 | Distinguished Scientist, Strategic Leader & Director |
Mark E. Davis | - | 2012 | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
Noreen Roth Henig | 59 | 2019 | Independent Director |
Carsten Boess | 58 | 2020 | Independent Director |
Edward M. Kaye | 75 | 2019 | Independent Director |
Simona Skerjanec | - | 2024 | Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核